BridgeBio Pharma, Inc. (BBIO)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-market:
| Previous close | 27.03 |
| Open | 27.60 |
| Bid | 27.73 x 700 |
| Ask | 27.79 x 700 |
| Day's range | 26.59 - 27.87 |
| 52-week range | 12.75 - 44.32 |
| Volume | |
| Avg. volume | 1,693,645 |
| Market cap | 5.191B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
BridgeBio Pharma First Quarter 2024 Earnings: Beats Expectations
BridgeBio Pharma ( NASDAQ:BBIO ) First Quarter 2024 Results Key Financial Results Revenue: US$211.1m (up by US$209.3m...
- Zacks
Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know
BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Bayer (BAYRY) Acquires BridgeBio's Cardiovascular Drug
Bayer (BAYRY) acquires exclusive marketing rights for cardiovascular drug acoramidis in Europe from BridgeBio for an upfront payment of $310 million.
© 2024 Yahoo. All rights reserved.